HEM Pharma Inc.

Microbiome biotech using analysis for personalized probiotics, LBPs, and full CDMO services.

376270 | KO

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: South Korea
Address:: 경기도 수원시 영통구 창룡대로256번길 50 711호, 수원시
Website:: https://hempharma.bio/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

HEM Pharma Inc. is a biotechnology company specializing in human microbiome research and technology. The company develops personalized healthcare solutions, probiotics, health functional foods, and Live Biotherapeutic Products (LBPs). Its core competency lies in its proprietary Personalized Microbiome Analysis System (PMAS), a screening platform used to identify and develop customized microbial solutions based on multi-omics and metabolome analysis. HEM Pharma also utilizes its MBR high-concentration fermentation technology for efficient production and offers Contract Development and Manufacturing Organization (CDMO) services through its GMP-certified facilities, supporting the entire lifecycle of microbiome-based products from research to manufacturing.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for HEM Pharma Inc. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all HEM Pharma Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for HEM Pharma Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Eisai Co., Ltd. A global, research-based pharmaceutical firm that develops and markets prescription and OTC drugs.	Japan	4523
Elicera Therapeutics AB Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.	Sweden	ELIC
Ellen AB Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.	Sweden	ELN
Enlivex Therapeutics Ltd. Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.	Israel	ENLV
Enorama Pharma AB Develops & makes consumer nicotine products & medicated gums, offering private label solutions.	Sweden	ERMA
ENZYCHEM LIFESCIENCES CORPORATION Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.	South Korea	183490
Enzymatica AB Develops medical devices with patented enzyme technology to treat upper respiratory infections.	Sweden	ENZY
Epi Biotech Co., Ltd. Developing alopecia therapies, skin regeneration products, and preclinical CRO services.	South Korea	446440
EQL Pharma AB Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.	Sweden	EQL
ERYTECH Pharma S.A. Developing phage therapies to combat antibiotic-resistant bacterial infections.	France	ERYP